ADMA Biologics Darbinieki 2024

Ko dara ADMA Biologics?

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.